In the Boardroom
Refine search
Pharmaceutical
AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK. 8 January 2026
Biotechnology
Israeli-US biotech Biolojic Design has named experienced oncologist Roger Waltzman as chief medical officer, strengthening its leadership as it pushes forward a growing pipeline of artificial intelligence-designed antibody medicines in oncology and immunology. 8 January 2026
Pharmaceutical
UK biotech AstronauTx has appointed Adam Rosenberg as chairman of its board, succeeding Tim Edwards, as the company advances its sleep architecture-focused approach to treating Alzheimer’s disease and other neurological disorders. The appointment comes as AstronauTx prepares to move its programs toward early clinical development. 7 January 2026
Biotechnology
New York-based clinical-stage biotech LB Pharmaceuticals had announced the appointments of Ellen Rose as senior vice president, corporate affairs and Lindsay Beaupre as SVP people and culture. 7 January 2026
Biotechnology
Syncromune, a privately-held US biopharma developing SYNC-T, an in-situ platform combination immunotherapy optimized for solid tumor cancers, has announced the appointment of Stephen Dale as chief medical officer (CMO). 6 January 2026
Biotechnology
Dutch immunology company argenx announced that Karen Massey, current chief operating officer, will transition to chief executive (CEO) and executive director, and Tim Van Hauwermeiren, current chief executive, will transition to non-executive director and chairman. 6 January 2026
Biotechnology
Chris Murphy has been appointed chief executive of privately-held US genetic medicines company, ElevateBio, also joining its board of directors. 5 January 2026
Generics
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
Pharmaceutical
Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle, today announced several leadership changes. 5 January 2026
Biotechnology
German drug discovery company Evotec has announced the appointment of Dr Sarah Fakih as executive vice president, head of global communications and investor relations. 2 January 2026
Biotechnology
Charlie Gayer will become BioCryst's new chief executive effective January 1. 30 December 2025
Biotechnology
USA and Europe listed biotech PureTech has appointed Robert Lyne as chief executive (CEO), and as a member of the board of directors, effective immediately. 18 December 2025
Biotechnology
Switzerland-based Topadur Pharma, a biotech company developing innovative therapies for vascular regeneration, has announced the appointment of Matthias Schäfer as chief executive. 17 December 2025
Pharmaceutical
US clinical-stage oncology company NanOlogy has appointed David Arthur as chief executive, as it accelerates development of its large surface area microparticle drug platform and prepares a regulatory filing for a rare pediatric brain cancer program. 17 December 2025
Pharmaceutical
UK based liquid medicines maker Rosemont Pharmaceuticals has appointed an American chief executive (CEO) as the business continues to expand into the USA, Canadian and European pharma market. 16 December 2025
Biotechnology
Swedish rare disease specialist Hansa Biopharma announced a reorganization of its European and International Commercial and Medical Affairs operations. 15 December 2025
Biotechnology
California, USA-based biotech Prolynx, which is developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, has announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as chief executive (CEO). 12 December 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK-Abello has appointed Edward Jordan as new executive vice president (EVP) and head of commercial operations in North America, effective January 5, 2026. 3 December 2025
Biotechnology
Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors. 2 December 2025
Biotechnology
Privately-held German biotech Tacalyx has appointed Jean Engela as chief executive (CEO). 2 December 2025
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Pharmaceutical
US biotech Conexeu Sciences has added three directors to its board and named co-founder David Bogart as chief commercial officer, as the newly listed company looks to put more commercial muscle behind its regenerative tissue platform. 16 June 2026
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Biotechnology
Sweden’s Hansa Biopharma announced today the appointment of Adam Cutler as chief financial officer (CFO) and a member of the executive committee, effective June 22, 2026. 15 June 2026
Pharmaceutical
Canada-based clinical-stage drug developer ZYUS Life Sciences Corporation yesterday announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. 12 June 2026
Biotechnology
Spanish women’s health biotech company Oriva Therapeutics has appointed Agnès Arbat as chief executive, as it advances a pipeline of treatments for chronic gynecological diseases led by the Phase I endometriosis candidate ORV-362. 11 June 2026
Biotechnology
UK biotech PhoreMost today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. 10 June 2026
Biotechnology
German biotech CatalYm has appointed Peter Garcia as chief financial officer, adding a seasoned life sciences finance executive as its lead asset, visugromab, moves through a broad mid- to late-stage clinical program. 10 June 2026
Biotechnology
Swedish rare diseases company Hansa Biopharma today announced that Fredrik Röök has been appointed as vice president business development effective August 17. 10 June 2026
Pharmaceutical
Australia’s clinical-stage radiopharma company today announced the appointment of Justyna Kelly as chief technology officer (CTO) and François Gaudet as chief scientific officer (CSO), expanding the company’s executive leadership team in the USA as it continues to scale its US capabilities, and advance its growing pipeline of innovative targeted alpha therapies. 8 June 2026
Biotechnology
US biotech Cocrystal Pharma has appointed James Sapirstein as its chief executive (CEO), effective immediately. 3 June 2026
Pharmaceutical
US clinical-stage pharma Altesa BioSciences has appointed Brett Haumann to its board and Gwen Skloot as senior vice president of clinical development, adding respiratory drug development experience as it advances vapendavir in chronic obstructive pulmonary disease (COPD). 3 June 2026
Biotechnology
US late-stage cell therapy developer ProKidney has announced the appointment of Kenneth Locke as chief technical officer. 3 June 2026
Biotechnology
Australian oncology-focused biotech Kazia Therapeutics today announced the appointment of James Levine as chief financial officer (CFO), effective June 1, 2026. Mr Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies. 2 June 2026
Biotechnology
German biotech FundaMental Pharma has appointed Hans Eriksson as chief medical officer, bringing in a depression drug development veteran as it prepares IND-enabling studies for its lead preclinical candidate, FMP374. 2 June 2026
Biotechnology
US biotech Capricor Therapeutics just named Michael Maurer as Chief Commercial Officer as the company heads toward an August 22 PDUFA date for deramiocel, its cell therapy for Duchenne muscular dystrophy. 30 May 2026
Pharmaceutical
Swiss clinical-stage biotech Topadur has appointed Felix Ehrat and Peter Jager to its board of directors, adding senior legal, governance and pharmaceutical industry experience as the company prepares for its next stage of growth. 28 May 2026
Biotechnology
US biotech Immunic today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as chief executive (CEO), effective May 22, 2026, with employment beginning on June 1, 2026. 27 May 2026
Generics
The UK subsidiary of German generics, biosimilars and consumer healthcare major STADA Arzneimittel is investing a seven-figure sum in an expanded, state-of-the-art commercial office in Green Park, Reading, as it advances its ambition of establishing the business as a British consumer healthcare and pharmaceutical powerhouse. 27 May 2026
Pharmaceutical
Jeffery Taubenberger, the acting director of the US National Institute of Allergy and Infectious Diseases (NIAID), has stepped down from the role, according to reports citing congressional Democrats and sources familiar with the matter. 22 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze